Harnessing Fc receptor biology in the design of therapeutic antibodies
Current Opinion in Immunology, ISSN: 0952-7915, Vol: 40, Page: 78-87
2016
- 85Citations
- 154Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations85
- Citation Indexes61
- 61
- CrossRef59
- Patent Family Citations24
- Patent Families24
- Captures154
- Readers154
- 154
- Mentions1
- News Mentions1
- News1
Most Recent News
Fusing a Novel Anti-CTLA-4 Nanobody to the IgG1 Fc Region Strengthens Its Ability to Induce CD8+ T Cell-Mediated Immune Responses Against Solid Tumors
Introduction Adoptive cell therapy, in which autologous or allogeneic CD8+ T cells are exposed to tumor antigens in vitro and then injected into cancer patients,
Review Description
The antibody Fc domain engages the small family of Fc receptors, expressed on cells of the immune system and beyond, to stimulate a rich diversity of positive and negative cell-mediated effector functions. The emergence of monoclonal antibodies for the treatment of various pathologic conditions has provided additional insights into Fc receptor biology, and has suggested new strategies to exploit Fc receptor interactions to create improved therapeutics. While most therapeutic IgGs approved to date have retained a native IgG Fc domain, the knowledge gained over the last decades has provided the opportunity to design tailored and more efficacious immunotherapies exhibiting fewer side effects and longer half-life. This review summarizes recent advances made in the design of biologics that modulate or exploit Fc receptor-IgG interactions, and describes innovative drugs currently under investigation in clinical trials that have been precisely tuned to achieve a desired therapeutic effect.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S095279151630022X; http://dx.doi.org/10.1016/j.coi.2016.03.005; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84962208068&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/27038127; https://linkinghub.elsevier.com/retrieve/pii/S095279151630022X; https://dx.doi.org/10.1016/j.coi.2016.03.005
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know